Filing Flows › ImmunityBio (IBRX) › Next earnings date
ImmunityBio (IBRX) earnings on Nov 9, 2026: what to expect
ImmunityBio (IBRX) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.05 (−$0.09 to $0.00, 3 estimates) on revenue of $59.2M, against −$0.07 and $32.1M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 65% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.07 on revenue of $75.8M, against the analysts' −$0.05.
The last report
ImmunityBio reported revenue of $51.2M for the second quarter 2026 (+94% Y/Y), net loss $230M: Product revenue, net $50.7M, Other revenues $568K. How it makes money → · Every quarter →
ImmunityBio's latest quarter
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
Questions
When does IBRX report earnings?
ImmunityBio is expected to report on Nov 9, 2026 (estimated).
What are analysts expecting from ImmunityBio?
EPS of −$0.05 and revenue of $59.2M for the quarter.
Does ImmunityBio usually beat earnings?
It beat the consensus EPS estimate in 50% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.